Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Biocept, Inc. - Common Stock (NQ: BIOC )

N/A UNCHANGED
Last Price Updated: 4:00 PM EDT, Oct 24, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Biocept, Inc. - Common Stock

< Previous 1 2 3 4 5 6 Next >
Earnings Outlook For Biocept
Biocept (NASDAQ:BIOC) is set to give its latest quarterly earnings report on Thursday, 2022-03-31. Here's what investors need to know before the announcement. Analysts estimate that Biocept will report... 
Via Benzinga
The Daily Biotech Pulse: Roche's Lung Cancer Combo Therapy Flunks Late-Stage Study, Adagio Spikes On Positive COVID Antibody Data, Amylyx Awaits Adcom Verdict
Here's a roundup of top developments in the biotech space over the last 24 hours. 
Via Benzinga
Biocept to Report 2021 Fourth Quarter and Full Year Financial Results on March 31, 2022
From Biocept, Inc.
Via Business Wire
The Week Ahead In Biotech (March 27-April 2): Lipocine, Akebia, Merck Await FDA Verdicts, Adcom Test For Amylyx, BioNTech Earnings And More
Biotech stocks reversed course in the week ending March 25, as an increase in risk appetite prompted traders to move money out of defensives and into risky bets. 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
Gainers Revelation Biosciences (NASDAQ:REVB 
Via Benzinga
Biocept Presentation at Molecular Medicine Tri-Con Meeting Highlights Potential of CNSide™ Assay to Support Development of Targeted Therapies for Metastatic Brain Cancer
From Biocept, Inc.
Via Business Wire
Biocept Appoints Samuel D. Riccitelli as Interim President and Chief Executive Officer and Antonino Morales as Interim Chief Financial Officer
From Biocept, Inc.
Via Business Wire
Biocept Names Darrell Taylor as Senior Vice President, General Counsel and Chief Compliance Officer
From Biocept, Inc.
Via Business Wire
Introduction of Innovative PCR-Based Detection Methods Surges Fueled by Pandemic and Other Diseases
Palm Beach, FL – February 18, 2022 – FinancialNewsMedia.com News Commentary – PCR testing and the COVID-19 diagnostic testing market has, unexpectantly, been growing at a substantial rate the past few... 
Via FinancialNewsMedia
Topics Intellectual Property
Exposures COVID-19 Intellectual Property
Biocept Reports an Increase in COVID-19 RT-PCR Testing Volume with Spread of the Omicron Variant
From Biocept, Inc.
Via Business Wire
Biocept to Present at the H.C. Wainwright BioConnect Virtual Conference on January 10
From Biocept, Inc.
Via Business Wire
Biocept’s CNSide Cerebrospinal Fluid Assay Identifies Actionable HER2 Mutations in Patients with Breast Cancer that has Metastasized to the Brain
From Biocept, Inc.
Via Business Wire
Biocept Launches Combined COVID-19 and Influenza Test to Provide Answers During Peak Flu Season
From Biocept, Inc.
Via Business Wire
CORRECTING and REPLACING Biocept’s CNSide Cerebrospinal Fluid Assay Aids in Monitoring Treatment Response and Detects Actionable Biomarkers in Patients with Metastatic Breast Cancer
From Biocept, Inc.
Via Business Wire
Biocept’s CNSide Cerebrospinal Fluid Assay Aids in Monitoring Treatment Response and Detects Actionable Biomarkers in Patients with Metastatic Breast Cancer
From Biocept, Inc.
Via Business Wire
Biocept Reports Third Quarter 2021 Financial Results
From Biocept, Inc.
Via Business Wire
The Week Ahead In Biotech (Nov. 14-Nov. 20): BioMarin FDA Decision, Tapering Earnings News Flow, Conference Presentations And More
Biotech stocks declined for the second straight week amid a broader market pullback, along with earnings news from small- and micro-cap companies and presentations at... 
Via Benzinga
Exposures Product Safety
Study Shows Biocept’s Switch-Blocker Technology Enhances Performance of Conventional PCR-Based Liquid Biopsy Assays in Detecting Rare Cancer Mutations
From Biocept, Inc.
Via Business Wire
Biocept to Report Third Quarter 2021 Financial Results and Host Investor Conference Call on November 15, 2021
From Biocept, Inc.
Via Business Wire
Biocept to Present at the LD Micro Main Event on October 13
From Biocept, Inc.
Via Business Wire
Biocept: A New Diagnostic Approach to Improve the Lives of Cancer Patients
Battling cancer is often a long journey—and one that becomes even more challenging for the large number of patients who find that the cancer may have spread to their brain... 
Via Benzinga
Biocept Implements COVID-19 Testing Program at Select California Community Colleges, Supporting Testing Needs for Students and Staff Amid Pandemic
From Biocept, Inc.
Via Business Wire
Biocept to Present Data at RAS-Targeted Drug Development Summit Showing Ability of Its Switch-BlockerTM Technology to Detect Rare Cancer Mutations
From Biocept
Via Business Wire
Biocept to Present at Four Virtual Investor Conferences in September
From Biocept
Via Business Wire
Biocept Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Biocept, Inc.
Via Business Wire
The Daily Biotech Pulse: Cara's Korsuva Greenlighted By FDA, Clinical Trial Disappointments For Novartis, Theravance, Vertex Inks CRISPR Licensing Deal
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 23) AbbVie Inc. (NYSE: ABBV) (... 
Via Benzinga
Exposures Product Safety
38 Stocks Moving In Friday's Mid-Day Session
Gainers GeoVax Labs, Inc. (NASDAQ: GOVX) shares climbed 45.8% to $6.27 after the company presented data from ongoing studies of its preventive vaccine against COVID-19, showing... 
Via Benzinga
Exposures COVID-19
22 Stocks Moving in Friday's Pre-Market Session
Gainers GeoVax Labs, Inc.. (NASDAQ: GOVX) shares rose 72.1% to $7.40 in pre-market trading after the company announced it presented COVID-19 vaccine data at the European Society... 
Via Benzinga
Exposures COVID-19
Investors React Positively To Study Data Of Biocept's Cerebrospinal Fluid Assay
Biocept Inc (NASDAQ:BIOC) has announced new d... 
Via Benzinga
Biocept’s CNSide Assay Identifies Tumor Cells and Actionable Treatment Biomarkers from Cerebrospinal Fluid in Patients with Metastatic Non-Small Cell Lung Cancer
From Biocept, Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.